Boceprevir as a viable HCV treatment: Making dosage more manageable

被引：0
|
作者：
Santori, Clarissa [1 ]
Fritsche, Melanie [1 ]
Andes, Amy [1 ]
Kresse, Isaac [1 ]
Jones, Graham [1 ]
机构：
[1] Northeastern Univ, Chem, Boston, MA 02115 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2016年 / 251卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
135
引用
收藏
页数：1
相关论文
共 50 条
  • [21] IMPACT OF RIBAVIRIN ON HCV REPLICON RNA DECLINE DURING TREATMENT WITH INTERFERON ALFA AND THE PROTEASE INHIBITORS BOCEPREVIR OR TELAPREVIR
    Hofmann, Wolf P.
    Chung, Tje Lin
    Osbahr, Carola
    Susser, Simone
    Karey, Ursula
    Welsch, Christoph
    Loetsch, Joern
    Sarrazin, Christoph
    Zeuzem, Stefan
    Herrmann, Eva
    HEPATOLOGY, 2010, 52 (04) : 1210A - 1210A
  • [22] Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir
    Hofmann, Wolf Peter
    Chung, Tje Lin
    Osbahr, Carola
    Susser, Simone
    Karey, Ursel
    Mihm, Ulrike
    Welsch, Christoph
    Loetsch, Joern
    Sarrazin, Christoph
    Zeuzem, Stefan
    Herrmann, Eva
    ANTIVIRAL THERAPY, 2011, 16 (05) : 695 - 704
  • [23] BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN FOR THE TREATMENT OF HCV/HIV CO-INFECTED PATIENTS: END OF TREATMENT (WEEK 48) INTERIM RESULTS
    Mallolas, J.
    Pol, S.
    Rivero, A.
    Fainboim, H.
    Cooper, C.
    Slim, J.
    Thompson, S.
    Wahl, J.
    Greaves, W.
    Sulkowski, M.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S22 - S22
  • [24] Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure
    Mattias Mandorfer
    Sebastian Steiner
    Philipp Schwabl
    Berit A. Payer
    Maximilian C. Aichelburg
    Katharina Grabmeier-Pfistershammer
    Michael Trauner
    Thomas Reiberger
    Markus Peck-Radosavljevic
    Wiener klinische Wochenschrift, 2016, 128 : 414 - 420
  • [25] Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure
    Mandorfer, Mattias
    Steiner, Sebastian
    Schwabl, Philipp
    Payer, Berit A.
    Aichelburg, Maximilian C.
    Grabmeier-Pfistershammer, Katharina
    Trauner, Michael
    Reiberger, Thomas
    Peck-Radosavljevic, Markus
    WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (11-12) : 414 - 420
  • [26] RESPONSE-GUIDED THERAPY (RGT) FOR BOCEPREVIR (BOC) COMBINATION TREATMENT? - RESULTS FROM HCV SPRINT-1
    Kwo, Paul Y.
    Lawitz, Eric
    McCone, Jonathan
    Schiff, Eugene R.
    Vierling, John M.
    Pound, David
    Davis, Mitchell
    Galati, Joseph S.
    Gordon, Stuart C.
    Ravendhran, Natarajan
    Rossaro, Lorenzo
    Anderson, Frank H.
    Jacobson, Ira M.
    Rubin, Raymond
    Koury, Kenneth
    Boparai, Navdeep
    Chaudhri, Eirum I.
    Brass, Clifford A.
    Albrecht, Janice K.
    HEPATOLOGY, 2009, 50 (04) : 1035A - 1036A
  • [27] HCV Treatment Decision-Making Substance Use Experiences and Hepatitis C Treatment Decision-Making Among HIV/HCV Coinfected Adults
    Ogawa, Lisa M. Fink
    Bova, Carol
    SUBSTANCE USE & MISUSE, 2009, 44 (07) : 915 - 933
  • [28] Gender more than IFN dosage determines rate of response in HCV plus chronic active hepatitis
    Esposito, P
    Cremonini, C
    Grottola, A
    Buttafoco, P
    Scarcelli, A
    Bertani, H
    Del Bueno, MG
    Giannini, F
    Manenti, F
    Villa, E
    JOURNAL OF HEPATOLOGY, 2000, 32 : 199 - 199
  • [29] Challenges in modern drug discovery: A case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection
    Njoroge, F. George
    Chen, Kevin X.
    Shih, Neng-Yang
    Piwinski, John J.
    ACCOUNTS OF CHEMICAL RESEARCH, 2008, 41 (01) : 50 - 59
  • [30] Gita Thanarajasingam: making treatment more tolerable
    Davies, Rachael
    LANCET HAEMATOLOGY, 2020, 7 (01): : E17 - E17
12345